Bisphenol A in Chronic Kidney Disease

Artificial Organs - Tập 37 Số 3 - Trang 283-290 - 2013
Detlef H. Krieter1, Bernard Canaud2, Horst‐Dieter Lemke3, A. Rodríguez2, A. Morgenroth4, K. von Appen5, G. P. Dragoun6, Christoph Wanner1
1Department of Medicine, Division of Nephrology University of Würzburg Würzburg
2Department of Nephrology Hôpital Lapeyronie University of Montpellier Montpellier France
3Research and Development Membrana GmbH Wuppertal
4Dialysis Center Elsenfeld
5Hamburger Dialyse Lohbrügge Hamburg
6KfH Center Aschaffenburg Germany

Tóm tắt

AbstractThe estrogenic endocrine‐disrupting substance bisphenol A (BPA) is extensively used as a starting material for a variety of consumer plastic products including dialyzer materials. The present study was performed to explore plasma BPA levels in patients with impaired renal function and to investigate if dialyzers differing in elutable BPA influence plasma levels in patients on maintenance hemodialysis. In vitro BPA was eluted from high‐flux polyethersulfone (PUREMA H, referred as PUR‐H), high‐flux polysulfone (referred as HF‐PSu), and low‐flux polysulfone (referred as LF‐PSu) dialyzers by recirculation with water for 180 min. In a cross‐sectional clinical study, plasma BPA levels of outpatients with different stages of chronic kidney disease (CKD) from four different centers were determined. Furthermore, in a prospective, randomized, and crossover setting, 18 maintenance dialysis patients were subjected successively to 4 weeks of thrice‐weekly hemodialysis with each LF‐PSu, HF‐PSu, and PUR‐H. In addition, the fractions of protein‐bound and free BPA were determined in a subset of dialysis patients. The mass of BPA eluted from the blood compartments in vitro under aqueous conditions varied for the three dialyzers being very low for PUR‐H (6.2 ± 2.5 ng; P < 0.001), intermediate for HF‐PSu (48.1 ± 7.7 ng), and highest for LF‐PSu (140.8 ± 38.7 ng; P < 0.01). In 152 prevalent patients with CKD enrolled in the cross‐sectional trial, plasma BPA started to rise after stage 3. Maintenance hemodialysis patients had more than six times higher BPA concentrations than patients with CKD stage 5 not yet on dialysis (10.0 ± 6.6 vs. 1.6 ± 1.8 ng/mL; P < 0.001). The BPA concentrations highly and inversely correlated with renal function. In the randomized controlled study, the plasma BPA concentrations were highly elevated compared with healthy controls (range 9.1 ± 4.5–12.0 ± 6.0 ng/mL vs. ≤0.2 ± 0.1 ng/mL; P < 0.001), but no change of the plasma levels was observed during hemodialysis with any of the three dialyzers in the course of a single treatment and over a period of 4 weeks. The protein‐bound fraction of plasma BPA in the dialysis patients was 74 ± 5%. Renal function and, most likely, the total quantity of ingested BPA are essential parameters affecting plasma BPA concentrations. Dialyzers are one additional source of BPA, but differences in the elutable BPA content are not associated with a significant effect on BPA plasma levels in Western European maintenance dialysis patients. Due to high protein binding, the removal of BPA by hemodialysis is limited.

Từ khóa


Tài liệu tham khảo

10.1016/j.reprotox.2007.07.010

10.1007/s00244-010-9634-y

10.1038/44517

10.1016/j.reprotox.2007.06.004

10.1007/s002040050659

Elsby R, 2001, Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans, J Pharmacol Exp Ther, 297, 103

10.1016/S0300-483X(03)00056-8

10.1210/jc.2002-020209

10.1111/j.1365-2605.2007.00832.x

10.1111/j.1365-2605.2007.00858.x

10.1210/er.2008-0021

10.3109/10408444.2011.558487

10.1016/j.reprotox.2007.06.008

10.1001/jama.300.11.1303

10.1371/journal.pone.0008673

10.1371/journal.pone.0026868

10.1210/jc.2011-1989

10.1016/j.envres.2011.05.014

10.1210/en.2005-1159

10.1159/000104869

10.1289/ehp.1002572

10.1002/1097-4636(2001)58:2<209::AID-JBM1009>3.0.CO;2-7

10.1159/000046023

10.1373/clinchem.2006.077180

10.1093/ndt/gfp437

Daugirdas JT, 2007, Handbook of Dialysis. Part II. Blood‐based Therapies, 25

10.1039/b103515k

10.1016/S0045-6535(98)00464-0

10.1016/j.tox.2006.06.009

10.1111/j.1744-9987.2007.00472.x

10.1097/00002480-197201000-00067

10.1007/s00204-002-0339-5

10.1016/j.jhazmat.2010.06.131

10.1007/978-0-585-36947-1_2

10.1289/ehp.021100703

Shelby MD, 2008, NTP‐CERHR monograph on the potential human reproductive and developmental effects of bisphenol A, NTP CERHR MON, 1

Thông tin
Thông tin xuất bản

Artificial Organs

Tập 37 Số 3

283-290

Thông tin tác giả